NCT06713369 AZD5305 hADME in Patients With Advanced Solid Malignancies

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 8 participants in total. It began in 2025-04-02 with a primary completion date of 2026-12-31.

Brief Summary

This Phase I, open-label study aims to study to absolute bioavailability of Saruparib (AZD5305) and the absorption, distribution, metabolism and excretion (ADME) of \[14C\]-Saruparib in patients with advanced solid malignancies. This will be done on an inpatient basis in 2 parts (single-dose oral administration with radiolabeled microtracer in Part A, single-dose IV radiolabeled administration in Part B) during which samples will be obtained of plasma, urine, feces and vomitus (where applicable).

Eligibility Criteria

Inclusion Criteria: 1. Male or female ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), at the time of signing the ICF. 2. Histologically or cytologically documented, locally advanced or metastatic solid tumour, excluding lymphoma, for which standard therapy does not exist or has proven ineffective or intolerable. 3. ECOG performance status of 0 or 1 with no deterioration over the 2 weeks prior to dosing. 4. Predicted life expectancy ≥ 12 weeks. 5. Adequate organ and marrow function as defined in the protocol 6. Willingness and ability to comply with study and follow-up procedures. 7. Able and willing to stay in hospital for specified residential periods following administration of Saruparib/\[14C\]-Saruparib 8. Regular bowel movements 9. Body weight within normal range specified in protocol 10. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies Reproduction 11. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol Exclusion Criteria: 1. Participants with a history of MDS/AML or with features suggestive of MDS/AML (as determined by prior diagnostic investigation). Specific screening for MDS/AML is not required. 2. Participants with any known predisposition to bleeding 3. Any history of persisting severe cytopenia due to any cause 4. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism, or excretion of Saruparib. 5. History of another primary malignancy, with some exceptions 6. Persistent toxicities (CTCAE Grade ≥ 2), excluding alopecia and peripheral neuropathy, caused by previous anticancer therapy. 7. Spinal cord compression or brain metastases for at least 4 weeks prior to start of study intervention unless asymptomatic and stable 8. Abnormal cardiac function exclusions or cardiovascular disease 9. History of arrhythmia 10. Active HBV (positive HBsAg result) or HCV. 11. Evidence of active and uncontrolled HIV infection. 12. Active tuberculosis infection 13. Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention or an anticipated need for major surgery during the study. 14. As judged by the investigator, any other evidence of diseases (such as severe or uncontrolled systemic diseases or active uncontrolled infections which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or would jeopardise compliance with the protocol. 15. Any prior treatment with Saruparib. 16. Other anticancer therapy (chemotherapy, immunotherapy, hormonal anticancer therapy, radiotherapy \[except for palliative local radiotherapy\]), biological therapy or other novel agent is not permitted until the last PK sampling is completed. 17. Palliative radiotherapy with a limited field of radiation within 2 weeks or with wide field of radiation or to more than 30% of the bone marrow within 4 weeks before the first dose of study intervention 18. Concomitant use of medications or herbal supplements known to be CYP3A4 strong inhibitors or inducers 19. Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes 20. Participants who have participated in another absorption, distribution, metabolism, and excretion study within 1 year prior to screening. 21. Participation in another clinical study with a study intervention administered in the last 1 month or 5 half-lives prior to dosing, whichever is longer. 22. Participants with a known hypersensitivity to Saruparib or any of the excipients of the product. 23. Participants who have been administered any amount of a \[14C\]-labelled compound within the last 12 months. 24. Use of tobacco- or nicotine-containing products or alcohol may be exclusionary 25. Poor peripheral venous access (venous access via a port will be permitted). 26. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site). 27. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. 28. Previous enrolment in the present study. 29. For female participants only: currently pregnant (confirmed with positive pregnancy test) or planning to become pregnant, breast-feeding, or intending to donate/retrieve ova before 6 months after the last dose of Saruparib.

Contact & Investigator

Frequently Asked Questions

Related Trials